1 week Ago By Defense World Staff
Norges Bank purchased a new position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 46,290 shares of the biotechnology company’s stock, valued at approximately $4,960,000. Norges Bank owned approximately 0.
24% of Ligand Pharmaceuticals at the end of the most recent quarter. Other hedge funds and other institutional investors have also recently modified their holdings of the company. Loomis Sayles & Co.
L P lifted its position in Ligand Pharmaceuticals by 6.7% during the fourth quarter. Loomis Sayles & Co.
L P now owns 397,700 shares of the biotechnology company’s stock valued at $42,614,000 after purchasing an additional 24,921 shares during the last quarter. Prudential Financial Inc. raised its stake in shares of Ligand Pharmaceuticals by 1.
3% during the fourth quarter. Prudential Financial Inc. now owns 102,995 shares of the biotechnology company’s stock valued at $11,036,000 after acquiring an additional 1,360 shares in the last quarter.
Congress Wealth Management LLC DE raised its holdings in shares of Ligand Pharmaceuticals by 4.4% in the fourth quarter. Congress Wealth Management LLC DE now owns 94,335 shares of the biotechnology company’s stock valued at $10,108,000 after acquiring an additional 4,014 shares in the last quarter.
Vanguard Group Inc. lifted its position in shares of Ligand Pharmaceuticals by 5.8% in the 4th quarter.
Vanguard Group Inc. now owns 2,085,627 shares of the biotechnology company’s stock worth $223,475,000 after purchasing an additional 115,005 shares during the period. Finally, KLP Kapitalforvaltning AS bought a new stake in Ligand Pharmaceuticals during the 4th quarter valued at $418,000.
Institutional investors own 91.28% of the company’s stock. Insider Transactions at Ligand PharmaceuticalsIn other Ligand Pharmaceuticals news, CFO Octavio Espinoza sold 5,000 shares of the firm’s stock in a transaction on Tuesday, March 4th.
The shares were sold at an average price of $115.03, for a total transaction of $575,150.00.
Following the completion of the transaction, the chief financial officer now directly owns 18,879 shares of the company’s stock, valued at $2,171,651.37. This trade represents a 20.
94 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 5.
90% of the company’s stock. Wall Street Analysts Forecast GrowthLGND has been the topic of several recent analyst reports. Royal Bank of Canada upped their target price on Ligand Pharmaceuticals from $141.
00 to $143.00 and gave the company an “outperform” rating in a research report on Wednesday, December 11th. Barclays upped their price target on shares of Ligand Pharmaceuticals from $150.
00 to $160.00 and gave the company an “overweight” rating in a report on Monday, December 16th. Benchmark reaffirmed a “buy” rating and set a $135.
00 price objective on shares of Ligand Pharmaceuticals in a research note on Monday, December 23rd. StockNews.com lowered Ligand Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday.
Finally, HC Wainwright restated a “buy” rating on shares of Ligand Pharmaceuticals in a research report on Wednesday, December 11th. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.
com, the company has a consensus rating of “Moderate Buy” and an average target price of $147.00.Get Our Latest Stock Analysis on Ligand PharmaceuticalsLigand Pharmaceuticals Trading Up 7.
4 %Shares of Ligand Pharmaceuticals stock opened at $103.85 on Thursday. Ligand Pharmaceuticals Incorporated has a 12-month low of $67.
72 and a 12-month high of $129.90. The stock has a market cap of $2.
00 billion, a PE ratio of 41.37 and a beta of 1.07.
The company has a 50-day moving average of $111.33 and a two-hundred day moving average of $111.92.
Ligand Pharmaceuticals Profile (Free Report)Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children.Featured ArticlesFive stocks we like better than Ligand PharmaceuticalsHow to Start Investing in Real EstateQuantum Computing: The $6.
5 Billion Opportunity You Can’t Ignore3 Natural Gas Stocks That Offer Great Dividend YieldsAre Tariffs Threatening Disney’s Comeback Story?Technology Stocks Explained: Here’s What to Know About TechIs Alphabet a Generational Buying Opportunity at These Levels?.
